AP

Aptabio Therapeutics Inc.

Develops drugs for intractable diseases by regulating oxidative stress and CAFs.

293780 | KO

Overview

Corporate Details

ISIN(s):
KR7293780003
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 흥덕1로 13 타워동 에이504호(영덕동, 흥덕아이티밸리), 용인시

Description

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-04-02 00:00
주식등의대량보유상황보고서(일반)
Korean 105.0 KB
2024-03-29 00:00
주식등의대량보유상황보고서(약식)
Korean 56.4 KB
2024-03-28 00:00
주식등의대량보유상황보고서(약식)
Korean 56.7 KB
2024-03-28 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 8.6 KB
2024-03-27 00:00
정기주주총회결과
Korean 30.8 KB
2024-03-25 00:00
전환가액의조정
Korean 16.6 KB
2024-03-25 00:00
기타경영사항(자율공시) (전환우선주의 전환가액 조정)
Korean 14.2 KB
2024-03-19 00:00
감사보고서제출
Korean 25.9 KB
2024-03-19 00:00
사업보고서 (2023.12)
Korean 1.4 MB
2024-03-12 00:00
[기재정정]주주총회소집결의
Korean 22.6 KB
2024-03-12 00:00
주주총회집중일개최사유신고
Korean 5.8 KB
2024-03-12 00:00
주주총회소집공고
Korean 155.0 KB
2024-02-06 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.3 KB
2024-02-06 00:00
주주총회소집결의
Korean 16.4 KB
2023-12-11 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB

Automate Your Workflow. Get a real-time feed of all Aptabio Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptabio Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptabio Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.